The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Open accessAbstract
BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years. RESULTS: The overall mean low-density lipoprotein cholesterol level was 26.5% lower in the rosuvastatin group than in the placebo group. The first coprimary outcome occurred in 235 participants (3.7%) in the rosuvastatin group and in 304 participants (4.8%) in the placebo group (hazard ratio, 0.76; 95% confidence interval [CI], 0.64 to 0.91; P=0.002). The results for the second coprimary outcome were consistent with the results for the first (occurring in 277 participants [4.4%] in the rosuvastatin group and in 363 participants [5.7%] in the placebo group; hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P<0.001). The results were also consistent in subgroups defined according to cardiovascular risk at baseline, lipid level, C-reactive protein level, blood pressure, and race or ethnic group. In the rosuvastatin group, there was no excess of diabetes or cancers, but there was an excess of cataract surgery (in 3.8% of the participants, vs. 3.1% in the placebo group; P=0.02) and muscle symptoms (in 5.8% of the participants, vs. 4.7% in the placebo group; P=0.005). CONCLUSIONS: Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; HOPE-3 ClinicalTrials.gov number, NCT00468923.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, there are three large, randomized trials of statin versus placebo where specific cognitive tests were performed, and no differences were seen between statin and placebo (166-169).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, there are three large, randomized trials of statin versus placebo where specific cognitive tests were performed, and no differences were seen between statin and placebo (160–163).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [163]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Heart Outcomes Prevention Evaluation 3 (HOPE-3), published in 2016, showed that low-dose statin therapy reduced the composite cardiovascular outcome by 24% but had no significant effect on mortality.19”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“The effectiveness of statins for preventing the first occurrence and recurrence of stroke in Japanese populations was confirmed in a sub-analysis of the MEGA study620, 621) and in the JELIS study622).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [621]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Self-citationForouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31679-8 · Cited by 7,698
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
O'Donnell, M. J., Xavier, D., Liu, L., Zhang, H., Chin, S. L., Rao-Melacini, P., Rangarajan, S., Islam, S., Pais, P., McQueen, M. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60834-3 · Cited by 3,448
Self-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Forouzanfar, M. H., Alexander, L., Anderson, H. R., Bachman, V. F., Biryukov, S., Brauer, M., Burnett, R., Casey, D., Coates, M. M., Cohen, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00128-2 · Cited by 2,701
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Flagged first, then by citations
Research works printed but not linked: 1
- Sackett DL, 2000, CMAJ, 162, 1311
Cited by
Sorted by citations
Items 701–800 of 847
Rupturas de aneurisma de la aorta abdominal: técnicas específicas
Touma, J., Bosse, C., Marzelle, J., Desgranges, P., & Cochennec, F. (2021) · EMC - Cirugía General · doi:10.1016/s1634-7080(21)45066-4 · Cited by 1
Would You Recommend a Statin to This Patient for Primary Prevention of Cardiovascular Disease?
Smetana, G. W., Benson, M. D., Juraschek, S. P., & Burns, R. B. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0908 · Cited by 1
Cardiovascular Disease and Hypertension in Migrant Asian Populations in the West
Singh, A., Jauhar, R., & Diamond, J. A. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-030-95734-6_4 · Cited by 1
Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2
Murphy, E., Cooney, M. T., & McEvoy, J. W. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-16594-8_2 · Cited by 1
Repurposing statins for different pathologies. A jack-of-all-trades drug?
Rodrigues-Díez, R. R., Muñoz, A. T., Márquez‐Expósito, L., & Ruiz‐Ortega, M. (2023) · Anales de la Real Academia Nacional de Farmacia · doi:10.53519/analesranf.2023.89.01.02
HOPE-3 and SPRINT: two landmark trials with different outcomes?
Kostis, J. B., & Oparil, S. (2016) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2016.04.008 · Cited by 1
Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
Chao, J., & Bansilal, S. (2016) · Global Heart · doi:10.1016/j.gheart.2016.10.020 · Cited by 1
Statins alone or polypill for primary prevention of cardiovascular diseases
Hasani‐Ranjbar, S., & Ejtahed, H. (2016) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-016-0280-4 · Cited by 1
When and Why Statins Fail to Save Lives
Vos, E., Nguyen, P., Biron, P., & Rose, C. P. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.02.037 · Cited by 1
Labos, C., Brophy, J. M., Smith, G. D., Sniderman, A. D., & Thanassoulis, G. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310907 · Cited by 1
Stay Tuned on Statins: The New Panacea?
Schutgens, R. E. G. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000047 · Cited by 1
Perils of Observational Data Analyses
Robinson, J. G. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012490 · Cited by 1
Morales, A. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2019.04.012 · Cited by 1
Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes
Lopez-Ayala, P., Glarner, N., & Mueller, C. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2305917 · Cited by 1
Cardiovascular risk assessment: are we getting all the information we need?
Pirillo, A., & Catapano, A. L. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad247 · Cited by 1
Primärprävention: Noch mehr Patienten mit Statinen behandeln?
Overbeck, P. (2016) · CardioVasc · doi:10.1007/s15027-016-0848-4
Rashidi, K. (2016) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.16.0471
HOPE-3—Finding the positive in the negative
Bloch, M. J. (2016) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2016.06.001
Lnc-ing Common Polymorphisms to Statin Responsiveness at the MYLIP Locus
Khetarpal, S. A., & Millar, J. S. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001458
The Need to Interpret the Results of a Clinical Trial in the Context of Other Evidence
Wald, N., & Morris, J. K. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.08.015
Comentário a «Redução da pressão arterial e do colesterol em indivíduos sem doença cardiovascular»
Baptista, R. (2016) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2016.07.001
Providing Innovative Solutions in a Single Pill: Servier’s Portfolio in Hypertension
Mourad, J., & Guillerm, J.-C. (2016) · Future Cardiology · doi:10.2217/fca-2016-0053
Mishchenko, L. A., Svishchenko, Y. P., & Bozhenko, H. M. (2016) · HYPERTENSION · doi:10.22141/2224-1485.3.47.2016.76368
The Effect of Digital Health Intervention on Reducing Cardiovascular Risk—Reply
Anand, S. S., Middleton, C. A., & Lear, S. A. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4246
Leening, M. J. G. (2016) · RePub (Erasmus University Rotterdam)
‘Examine my kidneys and my heart’: linking renal and cardiovascular disease
Tietge, U. J. F. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000379
Umeh, G., & Huffman, M. D. (2017) · Heart Asia · doi:10.1136/heartasia-2017-010898
Resúmenes de las Conferencias Diabetes, Obesidad y Lípidos
y Metabolismo, A. C. D. E. D. (2017) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.4.2.112
Lloyd‐Jones, D. M. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.2288
Гиляревский, С. Р., Kuzmina, I. M., Golshmid, M. V., Юрьевна, З. Г., & Sinitsina, I. I. (2016) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2016-2-106-116
Statines na je 65e, een kwestie van maatwerk
Pleumeekers, B. (2017) · Huisarts en Wetenschap · doi:10.1007/s12445-017-0235-0
Effect of antihypertensive treatment at different blood pressure levels
Brunström, M. (2017) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Statin guidelines: Friend or foes?
Masi, S., Taddei, S., & Virdis, A. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318768941
Hitting Hard and Early: A Novel Paradigm for Lipid Lowering in Primary Prevention
Lautsch, D., & Gitt, A. K. (2018) · Cardiology · doi:10.1159/000488972
Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials?
Bansal, M., & Agarwala, R. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.06.010
New data on the use of rosuvastatin and acetylsalicyl acid for the prolongation of human life
Владиславович, Е. М., & Laguta, P. S. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-6-12-18
Patient with coronary artery disease and hypertension
Lović, D. B., Đorđević, D., Tasic, I. S., Lovic, B., Stojanov, V., Jakovljević, B. D., & Nedeljkovic, M. A. (2018) · Srce i krvni sudovi · doi:10.5937/siks1801035l
Fall 37: Prävention – 47 Jahre, ♂, Prädiabetes, familiär gehäufte Schlaganfälle
Kihm, L. (2018) · Springer eBooks · doi:10.1007/978-3-662-55972-7_37
To Risk Stratify or Not for Statin Therapy
FITCHETT, D. H. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.01.009
Polypharmacy in very elderly hospitalised patients: a single centre study
Banakh, I. (2018) · Journal of Pharmaceutics and Therapeutics · doi:10.18314/jpt.v4i1.1139
Infográficos para decisão compartilhada no uso de estatinas em paciente de alto risco cardiovascular
Pinto, F. K. M. S., & de Oliveira, J. C. (2019) · Revista Brasileira de Medicina de Família e Comunidade · doi:10.5712/rbmfc14(41)1809
Manejo interprofesoral de las enfermedades cardiovasculares
López-Jaramillo, P. A., & Rueda-García, D. (2019) · Revista CUIDARTE · doi:10.15649/cuidarte.v10i2.756
Self-citationDrapkina, O. M., Владиславович, Е. М., Gilyarevsky, S. R., & Шепель, Р. Н. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-4-578-585 · Cited by 1
Gilyarevsky, S. R., Golshmid, M. V., Kuzmina, I. M., & Sinitsina, I. I. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-16-110-117
Mortensen, M. B., Fuster, V., Mehran, R., Baber, U., & Falk, E. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.001
Quoi de neuf en médecine interne ?
Jachiet, M., Rybojad, M., & Bouaziz, J. (2016) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(18)30046-2
Adverse effects of statins – Myths and facts
Prabhakar, D. (2019) · Journal of Indian College of Cardiology · doi:10.4103/jicc.jicc_35_19
Statins and the risk of cataract
Кронидовна, Б. Е., Бочкарева, Е. В., & Ким, И. В. (2019) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2019-6-75-79
Sánchez Vega, J. D., & Zamorano Gómez, J. L. (2019) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.34.3.27
症例解析＆文献評価ワークショップ2018 ： 脂質異常症 プリセプターの視点からの文献評価コースの報告と考察
茂木, 孝., 根本, 慎., 林, 洋., 本石, 寛., 藤田, 朋., 金井, 紀., 神山, 紀., 久保田, 洋., 小茂田, 昌., 佐藤, 弘., et al. (2018) · doi:10.24783/appliedtherapeutics.10.0_47
Mahmarian, J. J. (2020) · Journal of Nuclear Cardiology · doi:10.1007/s12350-020-02086-4
ERKRANKUNGEN DES HERZENS UND DES KREISLAUFS
Jung, N., Mayet, W.-J., Mertens, P. R., (federführend), J. M., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C.-M. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50011-5
Yang, I., & Cho, J. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001292
Orringer, C. E., & Stone, N. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_6
Petrik, N. I., Syrmilo, N. N., & Kovalyova, A. A. (2020) · Ukrainian Therapeutical Journal · doi:10.30978/utj2020-4-31
Primary prevention of Cardiovascular Diseases among the Middle aged and the Elderly
Omer, N. M. A. A., Yousuf, W., & Mansouri, N. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93997
Foot care among recently diagnosed diabetic patients in Muhayel, Aseer Region, Saudi Arabia
Hassan, A., Al-Khaldi, Y. M., Mawkili, B. M. K., Al-Mudawi, B. A. M., & Alasmari, A. A. A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93978
Rottura dell’aneurisma dell’aorta addominale: tecniche specifiche
Touma, J., Bosse, C., Marzelle, J., Desgranges, P., & Cochennec, F. (2021) · EMC - Tecniche Chirurgiche Vascolare · doi:10.1016/s1283-0801(20)44532-7
Aldhabaan, W. A., Asiri, B. B. S. A., & Alahmari, A. S. M. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93987
Minor Head Injury: Quality Improvement Project
Shaheen, S., Hameed, M., & Qabeel, Y. E. H. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93980
Management of depression in primary care - A cross-sectional study in the North-East of England, UK
Hegde, R., Gunputh, P., & Sinha, B. N. P. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93998
Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy
Bando, H., Kato, Y., Kato, Y., Matsuzaki, S., Waka, S., & Ogura, K. (2021) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2021/asjbccr.6233
Noninvasive Functional Evaluation of Coronary Microvascular Dysfunction
Park, J. (2021) · Journal of Cardiovascular Imaging · doi:10.4250/jcvi.2021.0041
News in the treatment of hypertension and dyslipidemia
Václavík, J. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.067
Approach to Primary Care of the Male Patient
Lamm, S. H., & Brill, K. (2020) · Springer eBooks · doi:10.1007/978-3-030-54482-9_3
Lee, J., Park, D., Cho, H. E., Kim, J. H., & Kim, H. S. (2021) · Research Square · doi:10.21203/rs.3.rs-779664/v1
Tratamiento con estatinas. La evidencia y el papel en la prevención primaria y secundaria
Morales-Villegas, E., & Ray, K. K. (2021) · Cardiovascular and Metabolic Science · doi:10.35366/100800
Dietary Approaches to Lowering LDL-C
Chevli, P. A., & Shapiro, M. D. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_13
Zhou, G., Wang, P., Lu, S., Wang, C., Xie, Z., Cao, W., Shi, J., Zhu, W., Wang, R., Zhou, G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3911102
Hyperlipidemia and the Role of Blood Lipids According to Iranian Traditional Medicine
Niknafs, A., rezvanfar, M., & Salehi, M. (2021) · Complementary Medicine Journal · doi:10.32598/cmja.11.2.844.2
Dislipidemias: terapêutica atual e perspectivas futuras na redução de riscos cardiovasculares
Lopes, M. G., & Sposito, A. C. (2018) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2018.17.3.19-23
A SAMSON nyomán: statinintolerancia, nocebohatás, adherencia
Márk, L., Reiber, I., Bajnok, L., & Paragh, G. (2021) · Cardiologia Hungarica · doi:10.26430/chungarica.2021.51.2.125 · Cited by 1
Directive clinique no 422e : Ménopause et maladies cardiovasculaires
Abramson, B. L., Black, D., Christakis, M. K., Fortier, M. P., & Wolfman, W. (2021) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2021.10.004
Estado, empresarios y restructuración: Argentina y México durante los ochenta
Patroni, V. (1999) · Acta científica venezolana
Toth, P. P. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_3
Zhang, Y., Zhao, X.-Q., Li, H., Ding, X., Li, D., Chen, H., & Li, W. (2020) · doi:10.21203/rs.3.rs-28625/v1
Rodríguez, Á. D., & Morató, T. M. (2022) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.10.008
Missikpode, C., Durazo-Arvizú, R., Cooper, R., O’Brien, M. J., Castañeda, S. F., Talavera, G., Gallo, L. C., Llabre, M. L., Perera, M. J., Perreira, K. M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-180873/v1
Fomin, I. V., & Георгиевна, В. Н. (2021) · Russian Medical Inquiry · doi:10.32364/2587-6821-2021-5-4-225-231
Comentário a «Redução da pressão arterial e do colesterol em indivíduos sem doença cardiovascular»
Baptista, R. (2016) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2016.08.002
Selvasudha, N., Koumaravelou, K., & Sridurga Devi, N. (2017) · SM Analytical and Bioanalytical Techniques · doi:10.36876/smabt.1013s
Association of red meat consumption with the incidence of cardiovascular diseasePreprint
Chrysant, S. G., & Chrysant, G. S. (2020) · doi:10.22541/au.159188513.38865745
Masson, W. M., Lobo, M., Huerin, M. S., Molinero, G., Lobo, L., & Nogueira, J. P. (2019) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2018.11.005
Gong, C., Liu, Q. P., Wang, J. M., Liu, X. F., Zhang, M. L., Yang, H., Shen, P., Lin, H., Tang, X., & Gao, P. (2022) · PubMed Central · doi:10.19723/j.issn.1671-167x.2022.03.008
Self-citationEthnic Factors in the Assessment of Cardiovascular Risk for Primary Prevention
Bhatia, H. S., Xu, I., Taub, P. R., & Wilkinson, M. J. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_11
Terapia combinada para la prevención cardiovascular: la ruta recorrida
López-Jaramillo, P. A., López-López, J., & Yusuf, S. (2021) · Revista Colombiana de Cardiología · doi:10.24875/rccar.m21000058
Self-citationNovel insights into determinants and prevention of atrial fibrillation progression
Nguyen, B. (2022) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.238296875
Statins and COVID-19: Review of Recommendations and Clinical Practice
Патеюк, И. В. (2022) · Рецепт · doi:10.34883/pi.2022.25.4.001
Rodríguez, Á. D., & Morató, T. M. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.08.001
Statin therapy for primary prevention in men: What is the role for coronary artery calcium?
Grundy, S. M., Wang, J., & Vega, G. L. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.11.001
Le patient à risque cardiovasculaire
Dibao-Dina, C., Lebeau, J., Boussageon, R., & Pouchain, D. (2022) · Elsevier eBooks · doi:10.1016/b978-2-294-76710-4.00013-9
Watson, K. E., Virani, S. S., & Stone, N. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00012-1
Гиляревский, С. Р. (2018) · Eurasian heart journal · doi:10.38109/2225-1685-2018-3-62-75
The Promise of Primary Prevention in Older Adults
Khan, S. U. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.005
Jia, W. P., Yang, Q., Lin, L., Zhu, C., & Jin, W. (2023) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2023.100007
Lipoprotein (a) Concentration is Inversely Related with Vertebral Arterial Flow
Naser, A. (2023) · BOĞAZİÇİ TIP DERGİSİ · doi:10.14744/bmj.2023.36744
Metadata
- Authors
- Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., Avezum, A., Piegas, L. S., Parkhomenko, A., Keltai, K., Keltai, M., Sliwa, K., Peters, R. J. G., Held, C., Chazova, I., Yusoff, K., Lewis, B. S., Jansky, P., Khunti, K., Toff, W. D., Reid, C. M., Varigos, J., Sanchez-Vallejo, G., McKelvie, R., Pogue, J., Jung, H., Gao, P., Diaz, R., & Lonn, E.
- Affiliations
- St. Michael's Hospital (CA)
- Semmelweis University (HU)
- Uppsala University (SE)
- ORCID
- Yusuf, Salim
- Bosch, Jackie
- Dagenais, Gilles
- Zhu, Jun
- Xavier, Denis
- Liu, Lisheng
- Pais, Prem
- López-Jaramillo, Patricio
- Leiter, Lawrence A.
- Piegas, Leopoldo S.
- Parkhomenko, Alexander
- Keltai, Katalin
- Sliwa, Karen
- Peters, Ron J.G.
- Held, Claes
- Chazova, Irina
- Yusoff, Khalid
- Lewis, Basil S.
- Khunti, Kamlesh
- Toff, William D.
- Reid, Christopher M.
- McKelvie, Robert
- Jung, Hyejung
- Lonn, Eva
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-05-26
- Volume
- 374
- Issue
- 21
- Pages
- 2021-2031
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2313998826
- Cited by
- 848
- References
- 23
- Citations by year
- 2026: 32 · 2025: 52 · 2024: 61 · 2023: 66 · 2022: 84 · 2021: 90 · 2020: 75 · 2019: 109 · 2018: 101 · 2017: 97 · 2016: 78
- FWCI
- 142.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Canadian Institutes of Health Research (IR2-91038))
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- rosuvastatin, statins, cholesterol lowering, intermediate cardiovascular risk, primary prevention, cardiovascular events, LDL cholesterol, ethnic diversity, C-reactive protein, cataract surgery, statin adverse effects, muscle symptoms, diabetes risk, cardiovascular mortality, myocardial infarction, stroke, heart failure, revascularization, cardiac arrest, cardiovascular risk stratification, lipid-lowering therapy
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
